UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor–Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems

Breast (Edinburgh), 2020-12, Vol.54, p.331-334

Mano, Max S.

2020

Volltextzugriff (PDF)

Trastuzumab emtansine: a game changer in HER2-positive early breast cancer

Future oncology (London, England), 2020-11, Vol.16 (32), p.2595-2609

Mano, Max

2020

Volltextzugriff (PDF)

Return to work after breast cancer diagnosis: An observational prospective study in Brazil

Cancer, 2018-12, Vol.124 (24), p.4700-4710

2018

Volltextzugriff (PDF)

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

Clinical drug investigation, 2023-09, Vol.43 (9), p.699-706

2023

Volltextzugriff (PDF)

Reply to R. Freitas-Junior et al

JCO global oncology, 2023-06, Vol.9 (9), p.e2300147-e2300147

2023

Volltextzugriff (PDF)

Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?

The lancet oncology, 2021-10, Vol.22 (10), p.1365-1366

Mano, Max S

2021

Volltextzugriff (PDF)

The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study

Breast (Edinburgh), 2020-12, Vol.54, p.46-51

2020

Volltextzugriff (PDF)

Borderline indications for ovarian suppression: addressing uncertainties with patients

Future oncology (London, England), 2022-12, Vol.18 (37), p.4111-4118

S Mano, Max

2022

Volltextzugriff (PDF)

Interfaces between medical practice and trading: lessons from the markets

Postgraduate medical journal, 2021-07, Vol.97 (1149), p.411-412

Mano, Max S

2021

Volltextzugriff (PDF)

If you can't kill the beast, tame it: Tips for surviving WhatsApp® in medical practice

Clinics (São Paulo, Brazil), 2023-01, Vol.78, p.100156-100156, Article 100156

Mano, Max S.

2023

Volltextzugriff (PDF)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

NPJ breast cancer, 2022-09, Vol.8 (1), p.106-6, Article 106

2022

Volltextzugriff (PDF)

More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings of the PREDIX HER2 trial

Annals of translational medicine, 2024-02, Vol.12 (1), p.16-16

Mano, Max S

2024

Volltextzugriff (PDF)

Physician leadership in private acquisitions: Styles for all situations

Clinics (São Paulo, Brazil), 2024-01, Vol.79, p.100443, Article 100443

2024

Volltextzugriff (PDF)

Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil

JCO global oncology, 2022-11, Vol.8 (8), p.e2200289-e2200289

2022

Volltextzugriff (PDF)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Biomarker research, 2018-06, Vol.6 (1), p.20-20, Article 20

2018

Volltextzugriff (PDF)

Implementing multidisciplinary tumor boards in oncology: a narrative review

Future oncology (London, England), 2022-01, Vol.18 (3), p.375-384

2022

Volltextzugriff (PDF)

Gene expression signatures in early breast cancer: Better together with clinicopathological features

Critical reviews in oncology/hematology, 2022-07, Vol.175, p.103708-103708, Article 103708

2022

Volltextzugriff (PDF)

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Clinical cancer research, 2023-04, Vol.29 (8), p.1569-1581

2023

Volltextzugriff (PDF)

Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting

Breast cancer (Tokyo, Japan), 2016-03, Vol.23 (2), p.261-265

2016

Volltextzugriff (PDF)

Telehealth, Social Media, Patient Empowerment, and Physician Burnout: Seeking Middle Ground

American Society of Clinical Oncology educational book, 2022-04, Vol.42 (42), p.1-37

2022

Volltextzugriff (PDF)

Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?

European radiology, 2022-03, Vol.32 (3), p.1663-1675

2022

Volltextzugriff (PDF)

Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil

The oncologist (Dayton, Ohio), 2022-05, Vol.27 (5), p.344-351

2022

Volltextzugriff (PDF)

Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer

Current oncology reports, 2021-05, Vol.23 (5), p.58, Article 58

2021

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(128)

Publikationsform

Artikel
(147)
Buchkapitel
(1)

Sprache

Englisch
(146)
Portugiesisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Life Sciences & Biomedicine
(77)
Oncology
(61)
Humans
(60)
Female
(44)
Breast Cancer
(39)
Chemotherapy
(28)
Breast Neoplasms - Drug Therapy
(26)
Middle Aged
(22)
Adult
(18)
Trastuzumab
(15)
Aged
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Patients
(14)
Treatment Outcome
(14)
Obstetrics & Gynecology
(13)
Breast Neoplasms - Pathology
(12)
Hematology, Oncology And Palliative Medicine
(12)
Cancer Therapies
(11)
Chemotherapy, Adjuvant
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor–Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems

Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial

Trastuzumab emtansine: a game changer in HER2-positive early breast cancer

Return to work after breast cancer diagnosis: An observational prospective study in Brazil

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate

Reply to R. Freitas-Junior et al

Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?

The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study

Borderline indications for ovarian suppression: addressing uncertainties with patients

Interfaces between medical practice and trading: lessons from the markets

If you can't kill the beast, tame it: Tips for surviving WhatsApp® in medical practice

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

More on treatment de-escalation, biomarkers of response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer: long-term outcomes and translational research findings of the PREDIX HER2 trial

Physician leadership in private acquisitions: Styles for all situations

Impact of the COVID-19 Pandemic on Cancer Staging: An Analysis of Patients With Breast Cancer From a Community Practice in Brazil

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy

Implementing multidisciplinary tumor boards in oncology: a narrative review

Gene expression signatures in early breast cancer: Better together with clinicopathological features

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting

Telehealth, Social Media, Patient Empowerment, and Physician Burnout: Seeking Middle Ground

Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?

Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil

Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer

Suchergebnisse filtern